Navigation Links
Research Identifies Need for Improved Understanding of Sickle Cell Disease in Adulthood
Date:12/8/2007

- Additional Data Show the Standard Treatment for Sickle Cell Disease is Widely Under-Prescribed in Some Populations -

ATLANTA, Dec. 8 /PRNewswire-USNewswire/ -- New research to be presented at the 49th Annual Meeting of the American Society of Hematology in Atlanta, GA, will provide important insight into the treatment and management of sickle cell disease and thalassemia, both disorders of the red blood cells. Specifically, data will be presented on advancements in iron chelation therapy, treatments necessary for patients who require multiple blood transfusions because of the risk of excess iron. Researchers will also unveil new findings about brain damage in sickle cell patients, a complication of the disorder that can occur as patients age. Additionally, retrospective and prospective trials among Florida Medicaid populations and patients in Nigeria, an area with the highest global burden of sickle cell disease, will show the need for physician education to address the underutilization of hydroxyurea, which is an efficacious treatment associated with a significant reduction in sickle cell complications, hospitalizations, and transfusion requirements by about 50 percent and in mortality by 40 percent. A press conference revealing this new research will take place Saturday, December 8, from 1:30 p.m. to 2:30 p.m.

"Sickle cell disease, once considered a fatal pediatric condition, is now a chronic adult illness. As physicians, we need to better understand how to treat sickle cell patients from childhood through their adult life," said press conference moderator Marilyn Telen, MD, Division Chief of Hematology, Duke University, Durham, NC. "Further, by understanding how to effectively mitigate the consequences of multiple transfusions, particularly iron overload, we can better serve a broad range of patients who suffer from red blood cell disorders."

-- Hydroxyurea, a highly efficacious treatment for sickle cell patients, is underutili
'/>"/>

SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced the ... of Warburg Pincus LLC, to the Amgen Board of Directors. ... Hassan and the deep, global experience he brings in ... A. Bradway , chairman and chief executive officer of Amgen. "Fred,s ... Amgen well." Mr. Hassan has been Partner and ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... YORK, Jan. 13, 2011 Reportlinker.com announces that ... its catalogue: Merck & Co., ... IntroductionThis analysis examines the ... in the prescription pharmaceutical sector. The profile encompasses ...
... Codexis, Inc. (Nasdaq: CDXS) today announced the company will host ... at 4:30 p.m. Eastern Time to discuss its fourth quarter ... call and webcast will follow the release of fourth quarter ... call will be available approximately one hour after the call ...
Cached Medicine Technology:Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on ... and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the ... allows users to clarify, edit and delete any message including ones already sent. , ...
(Date:7/31/2015)... Ind. (PRWEB) , ... August 01, 2015 , ... The ... the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in ... invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... run by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . ... which are customizable. The best part: whenever a product is purchased, the Meso ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin ... re-branded their social media profiles to better connect with the public. The agency ... find information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article ... see if they could reach a consensus on the steps that need to be ... the group reached 90 percent consensus on a series of steps that each surgeon ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Growth Initiatives, ROCHESTER, N.Y., Sept. 17 ... completed a private placement of,$4,350,000 of Series B ... institutional and other accredited investors. VirtualScopics,currently intends to ... expand its,sales and marketing efforts, software and technology ...
... Sept. 17 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that Edward F. Brennan, President and Chief,Executive Officer, and ... at the Maxim Group First Annual Growth Conference in,New ... a.m. ET at The Grand,Hyatt Hotel. A live ...
... St. Margaret,s Daughters, Home, NEW ORLEANS, Sept. 17 ... New Orleans will be reunited in a,temporary facility this ... Hurricane Katrina. The 116-bed eldercare facility was destroyed ... Ninth Ward. While everyone at St.,Margaret,s was evacuated safely ...
... John Brooke, General Manager of,Billian,s HealthDATA, leading provider ... ,07 Global Gathering, Salesforce.com,s 5th,Annual User and Developer ... is the ultimate gathering of the salesforce.com community,bringing ... and AppExchance,users spanning industries, roles and locales. Mr. ...
... time scientists have been able to film, in real ... DNA strand from an attacking virus. Researchers from the ... Force Microscope in Japan to produce amazing footage of ... trying to infect a bacterial host. , The ...
... may only be modestly accurate, according to researchers from the ... Carolina. In a study that appears in the October issue ... usefulness of a scale that asks patients in primary care ... 10 (worst pain). , Universal pain screening is ...
Cached Medicine News:Health News:VirtualScopics Announces $4.35 Million Private Placement 2Health News:VirtualScopics Announces $4.35 Million Private Placement 3Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:Renovated New Orleans Care Facility Reopens, Reuniting Residents and Staff 2Health News:Renovated New Orleans Care Facility Reopens, Reuniting Residents and Staff 3Health News:Billian's HealthDATA GM Speaking on Dreamforce 07 Panel 2Health News:Scientists reveal DNA-enzyme interaction with first ever real time footage 2Health News:Rating your pain from 0 to 10 might not help your doctor 2
Simply stated, no bone cement can match the history of Simplex™. Simplex™ is the only cement with 40 years of proven clinical performance - trusted by tens of thousands of surgeons with o...
DePuy 2 Bone Cement is a unique fast-set digital cement that is the excellent choice for small joint procedures such as the patella, glenoid or other extremity joints....
... John Charnley and CMW, Inc. began ... bone cements exclusively for orthopaedic applications. ... years of performance and excellence in ... one of the first proven bone ...
... Paradigm's Dicon Ocular Blood Flow Analyzer is ... increase your early diagnosis of low and ... (BFA) provides a fast, clinically proven measurement ... BFA assists in the management of glaucoma, ...
Medicine Products: